Search alternatives:
significant associations » significant association (Expand Search), significantly associated (Expand Search)
associations decrease » associations across (Expand Search), association areas (Expand Search), association created (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
Showing 1,721 - 1,740 results of 21,342 for search '(( significant decrease decrease ) OR ( significant associations decrease ))', query time: 0.50s Refine Results
  1. 1721
    Expression pattern of statistically significantly differentially expressed immune-related genes in CL patients compared to healthy volunteers.

    Expression pattern of statistically significantly differentially expressed immune-related genes in CL patients compared to healthy volunteers. by Nasrin Masoudzadeh (20300511)

    Published 2025
    “…(b) The bar plot indicates Log2FC of DEGs associated with Morocco and Iran lesions. The red and blue colors of the bar plot represent relative significant increased or decreased expression of the genes in patients compared to healthy samples. …”
    Save to List
    Saved in:
  2. 1722
    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…In addition, compound <b>E35</b> significantly inhibited colony formation and migration, as well as arrested the cell cycle at the S-phase. …”
    Save to List
    Saved in:
  3. 1723
    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…In addition, compound <b>E35</b> significantly inhibited colony formation and migration, as well as arrested the cell cycle at the S-phase. …”
    Save to List
    Saved in:
  4. 1724
    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…In addition, compound <b>E35</b> significantly inhibited colony formation and migration, as well as arrested the cell cycle at the S-phase. …”
    Save to List
    Saved in:
  5. 1725
    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…In addition, compound <b>E35</b> significantly inhibited colony formation and migration, as well as arrested the cell cycle at the S-phase. …”
    Save to List
    Saved in:
  6. 1726
    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…In addition, compound <b>E35</b> significantly inhibited colony formation and migration, as well as arrested the cell cycle at the S-phase. …”
    Save to List
    Saved in:
  7. 1727
    Fig 1 -

    Fig 1 - by Ingmar Lundquist (46422)

    Published 2025
    Save to List
    Saved in:
  8. 1728
    Root mean square deviation of wild-type AKR1C3 (green line) and mutant (H5Q) AKR1C3 (purple line) proteins.

    Root mean square deviation of wild-type AKR1C3 (green line) and mutant (H5Q) AKR1C3 (purple line) proteins. by Md. Akeruzzaman Shaon (21511929)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 1729
    The solvent accessible surface area (SASA) of wild-type (green line) AKR1C3 (complexed with the ligand, NADPH) was lower than that of the mutant (purple line) AKR1C3 (complexed with the ligand, NADPH).

    The solvent accessible surface area (SASA) of wild-type (green line) AKR1C3 (complexed with the ligand, NADPH) was lower than that of the mutant (purple line) AKR1C3 (complexed wit... by Md. Akeruzzaman Shaon (21511929)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 1730
    Hardy‒Weinberg equilibrium test of rs12529 in the study subjects.

    Hardy‒Weinberg equilibrium test of rs12529 in the study subjects. by Md. Akeruzzaman Shaon (21511929)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 1731
    Demographic characteristics of the breast cancer patients enrolled in the study.

    Demographic characteristics of the breast cancer patients enrolled in the study. by Md. Akeruzzaman Shaon (21511929)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 1732
    Root mean square fluctuations of the wild-type (green line) and mutant (H5Q) (purple line) proteins of AKR1C3 (complexed with the ligand NADPH).

    Root mean square fluctuations of the wild-type (green line) and mutant (H5Q) (purple line) proteins of AKR1C3 (complexed with the ligand NADPH). by Md. Akeruzzaman Shaon (21511929)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 1733
    Representative restriction enzyme-digested products on a 2% agarose gel.

    Representative restriction enzyme-digested products on a 2% agarose gel. by Md. Akeruzzaman Shaon (21511929)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 1734
    Baseline characteristics of study subjects.

    Baseline characteristics of study subjects. by Md. Akeruzzaman Shaon (21511929)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 1735
    The radius of gyration of wild-type and mutant (H5Q) AKR1C3 (both complexed with the ligand, NADPH).

    The radius of gyration of wild-type and mutant (H5Q) AKR1C3 (both complexed with the ligand, NADPH). by Md. Akeruzzaman Shaon (21511929)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 1736
    Functional effects of rs12529 (H5Q) on the AKR1C3 protein.

    Functional effects of rs12529 (H5Q) on the AKR1C3 protein. by Md. Akeruzzaman Shaon (21511929)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 1737
    The distribution of rs12529 (C15G) genotypes among participants categorized by menopausal status.

    The distribution of rs12529 (C15G) genotypes among participants categorized by menopausal status. by Md. Akeruzzaman Shaon (21511929)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 1738
    Frequency distribution of rs12529 (C15G) genotypes in breast cancer patients and control subjects.

    Frequency distribution of rs12529 (C15G) genotypes in breast cancer patients and control subjects. by Md. Akeruzzaman Shaon (21511929)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 1739
    The clinicopathological information of the patients involved in this study.

    The clinicopathological information of the patients involved in this study. by Md. Akeruzzaman Shaon (21511929)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 1740
    Genotypic distribution of rs12529 in the study subjects.

    Genotypic distribution of rs12529 in the study subjects. by Md. Akeruzzaman Shaon (21511929)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: